Valeant Provides Financial Guidance Update

Valeant (VRX) Credibility Issues Remain Despite Positive Update - Piper Jaffray; PT Cut to $133

Piper Jaffray analyst David Amsellem reiterated a Neutral rating and slashed his price target on Valeant Pharmaceuticals (NYSE: VRX) to $133.00 (from $193.00) following yesterday's Investor Day. The update was positive, but credibility issues remain, the analyst said.

Amsellem commented, "We attended Valeant's investor day,... More

Upward Earnings Revisions to Drive Valeant (VRX) Higher - Guggenheim

Guggenheim analyst Louise Chen reiterated a Buy rating and $195 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's analyst day. The analyst thinks upwards consensus earnings revisions and multiple expansion will drive VRX shares higher

Chen commented, "Post VRX's Investor Day on 12/16/15, we think upwards... More

Mizuho Securities Downgrades Valeant Pharmaceuticals (VRX) to Neutral

Mizuho Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Neutral with a price target of $130.00 (from $111.00).

Analyst Irina Koffler commented, "We still see modest upside in VRX valuation, even after the stock had an unexpectedly strong positive reaction to the Walgreens... More

Mizuho Securities Offers Takeways Following Valeant's (VRX) Investor Day

Mizuho Securities maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $111. Comments follow its investor day. Analyst Irina R. Koffler highlighted several takeways from the meeting. Notably, she said the financial benefit of its Walgreen's agreement remains difficult to quantify.

Koffler stated, "We see some modest upside... More

Valeant Pharmaceuticals (VRX) Guidance 'Probably Conservative' - BMO Capital

BMO Capital analyst Alex Arfaei said after a first look at Valeant Pharmaceuticals (NYSE: VRX) guidance he views it at "probably conservative."

Arfaei commented, "While some components of the guidance may appear disappointing, we suspect that it is conservative. About 7.2% of... More

Valeant Pharma (VRX) Sees Revenue Impact from Walgreens Deal at ~$150M for FY16

Valeant Pharma (NYSE: VRX) sees impact from Walgreens agreement at about $150 million for FY16. That translates to about $0.40 per share on earnings.

The Philidor separation will impact FY16 revenue by about $250 million and EPS by about $0.65.

Information comes from the company's investor presentation today, which is embedded below: